

Marie-Cécile Le Deley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3806514/publications.pdf>

Version: 2024-02-01

76
papers

5,593
citations

109321

35
h-index

82547

72
g-index

77
all docs

77
docs citations

77
times ranked

7430
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to H. B et al. Journal of Clinical Oncology, 2022, , JCO2102612.	1.6	1
2	MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 2022, 304, 174-182.	7.3	12
3	Neuroâ€meningeal relapse in anaplastic largeâ€cell lymphoma: incidence, risk factors and prognosis â€ a report from the European intergroup for childhood nonâ€Hodgkin lymphoma. British Journal of Haematology, 2021, 192, 1039-1048.	2.5	11
4	Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial. Journal of Clinical Oncology, 2021, 39, 2979-2990.	1.6	38
5	A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction. Cancers, 2021, 13, 4925.	3.7	2
6	WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro-Oncology, 2020, 22, 116-127.	1.2	26
7	Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers, 2020, 12, 2747.	3.7	38
8	Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial. Clinical Cancer Research, 2020, 26, 1856-1865.	7.0	10
9	Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial. BMJ Open, 2018, 8, e015904.	1.9	12
10	Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 619-628.	2.6	7
11	Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. European Journal of Cancer, 2018, 88, 57-66.	2.8	74
12	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. Journal of Clinical Oncology, 2018, 36, 951-958.	1.6	95
13	Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. BMC Cancer, 2018, 18, 963.	2.6	15
14	Variations in the breast reconstruction rate in France: A nationwide study of 19,466 patients based on the French medico-administrative database. Breast, 2018, 42, 74-80.	2.2	15
15	Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial. BMC Cancer, 2018, 18, 775.	2.6	2
16	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer, 2018, 99, 28-36.	2.8	13
17	Prevalence of herbal medicine (HM) use among breast cancer patients treated with chemotherapy, hormone therapy, or targeted therapy.. Journal of Clinical Oncology, 2018, 36, e13108-e13108.	1.6	2
18	Phase-II trials in osteosarcoma recurrences: A systematic review of past experience. European Journal of Cancer, 2017, 75, 98-108.	2.8	58

#	ARTICLE	IF	CITATIONS
19	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017, 7, 586-595.	9.4	554
20	RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. <i>European Journal of Cancer</i> , 2017, 83, 185-193.	2.8	19
21	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 189-198.	2.8	34
22	A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (>16 years) low grade glioma – A final report. <i>European Journal of Cancer</i> , 2017, 81, 206-225.	2.8	104
23	Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study. <i>BMC Cancer</i> , 2017, 17, 419.	2.6	3
24	Bayesian survival analysis in clinical trials: What methods are used in practice?. <i>Clinical Trials</i> , 2017, 14, 78-87.	1.6	18
25	DIPG-21. GENOMIC LANDSCAPE OF THE FIRST 100 TUMORS REGISTERED IN THE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL. <i>Neuro-Oncology</i> , 2017, 19, iv9-iv9.	1.2	1
26	Paclitaxel once weekly (wP) combined with fixed dose of oral metronomic cyclophosphamide (OMC): A dose-escalating phase I trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14015-e14015.	1.6	0
27	HG-85 INTER-OBSERVER AGREEMENT IN NEUROPATHOLOGICAL HGG DIAGNOSIS : EXPERIENCE OF THE PRE-RANDOMISATION CENTRAL REVIEW IN THE HERBY TRIAL. <i>Neuro-Oncology</i> , 2016, 18, iii68.1-iii68.	1.2	0
28	Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. <i>European Journal of Cancer</i> , 2016, 61, 128-136.	2.8	69
29	PDCT-07. HERBY (BO25041): A PHASE II OPEN-LABEL, RANDOMIZED, MULTICENTER, COMPARATIVE STUDY OF BEVACIZUMAB (BEV)-BASED THERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG). <i>Neuro-Oncology</i> , 2016, 18, vi146-vi147.	1.2	0
30	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1070-1080.	10.7	170
31	New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study. <i>Statistics in Medicine</i> , 2016, 35, 3245-3258.	1.6	8
32	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. <i>Clinical Cancer Research</i> , 2016, 22, 2960-2968.	7.0	103
33	Equal access to innovative therapies and precision cancer care. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 385-393.	27.6	43
34	Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). <i>European Journal of Cancer</i> , 2016, 59, 79-89.	2.8	36
35	Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer: Results of the AcSAR phase II trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11509-11509.	1.6	9
36	Late toxicity of brachytherapy after female genital tract tumors treated during childhood: Prospective evaluation with a long-term follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 206-212.	0.6	19

#	ARTICLE	IF	CITATIONS
37	Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial. <i>European Journal of Cancer</i> , 2015, 51, 2453-2464.	2.8	21
38	Primary cutaneous and subcutaneous Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1555-1561.	1.5	25
39	Risk of Subsequent Leukemia After a Solid Tumor in Childhood: Impact of Bone Marrow Radiation Therapy and Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 658-667.	0.8	15
40	Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. <i>Nature Genetics</i> , 2015, 47, 1073-1078.	21.4	157
41	Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. <i>Journal of Clinical Oncology</i> , 2015, 33, 2963-2974.	1.6	202
42	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 3036-3046.	1.6	516
43	Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. <i>European Journal of Cancer</i> , 2014, 50, 170-177.	2.8	47
44	Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. <i>Pediatric Blood and Cancer</i> , 2014, 61, 977-981.	1.5	43
45	Paediatric anaplastic large cell lymphoma with leukaemic presentation in children: a report of nine French cases. <i>British Journal of Haematology</i> , 2014, 165, 545-551.	2.5	18
46	Clinical analysis and prognostic significance of haemophagocytic lymphohistiocytosis-associated anaplastic large cell lymphoma in children. <i>British Journal of Haematology</i> , 2014, 165, 117-125.	2.5	7
47	Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2440-2448.	1.6	136
48	Central nervous system involvement in anaplastic large cell lymphoma in childhood: Results from a multicentre European and Japanese study. <i>Pediatric Blood and Cancer</i> , 2013, 60, E118-21.	1.5	29
49	Dose-finding designs using a novel quasi-continuous endpoint for multiple-toxicities. <i>Statistics in Medicine</i> , 2013, 32, 2728-2746.	1.6	45
50	Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Soci�t� Fran�saise d'Oncologie P�diatrique (SFOP), and International Society for Pediatric Oncology (SIOP). <i>Clinical Cancer Research</i> , 2012, 18, 2001-2011.	7.0	111
51	Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. <i>Clinical Trials</i> , 2012, 9, 283-292.	1.6	19
52	Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. <i>Cancer</i> , 2012, 118, 4981-4990.	4.1	44
53	Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4669-4676.	1.6	142
54	Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma. <i>Blood</i> , 2011, 117, 5616-5619.	1.4	21

#	ARTICLE	IF	CITATIONS
55	Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. <i>European Journal of Cancer</i> , 2011, 47, 230-238.	2.8	41
56	Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design. <i>European Journal of Cancer</i> , 2011, 47, 1647-1652.	2.8	9
57	Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: Report of the ALCL99 randomised trial. <i>Pediatric Blood and Cancer</i> , 2011, 56, 1071-1077.	1.5	46
58	Reply to N. Andr�� et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e92-e93.	1.6	0
59	Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. <i>Neuro-Oncology</i> , 2011, 13, 109-118.	1.2	137
60	Role of Radiation Dose in the Risk of Secondary Leukemia After a Solid Tumor in Childhood Treated Between 1980 and 1999. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1474-1482.	0.8	14
61	Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3987-3993.	1.6	169
62	Impact of <i>EWS-ETS</i> Fusion Type on Disease Progression in Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: Prospective Results From the Cooperative Euro-E.W.I.N.G. 99 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 1982-1988.	1.6	180
63	Operating characteristics of two independent sample design in phase I trials in paediatric oncology. <i>European Journal of Cancer</i> , 2010, 46, 1392-1398.	2.8	6
64	Abstract 852: Prognostic value of circulating endothelial and progenitor cells in advanced cancer patients enrolled in phase I in association with clinical prognostic scores. , 2010, , .		0
65	Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology. <i>Journal of Clinical Oncology</i> , 2009, 27, 5056-5061.	1.6	129
66	Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 897-903.	1.6	194
67	Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. <i>Blood</i> , 2008, 111, 1560-1566.	1.4	156
68	Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 292-300.	1.6	140
69	SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. <i>European Journal of Cancer</i> , 2007, 43, 752-761.	2.8	143
70	Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: A case��control study. <i>International Journal of Cancer</i> , 2007, 120, 96-102.	5.1	48
71	High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. <i>Pediatric Blood and Cancer</i> , 2005, 45, 25-31.	1.5	44
72	Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. <i>Lancet Oncology</i> , The, 2005, 6, 573-580.	10.7	250

#	ARTICLE	IF	CITATIONS
73	Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapy—Results of the First French Prospective Study for the French Society of Pediatric Oncology. <i>Journal of Clinical Oncology</i> , 2003, 21, 4572-4578.	1.6	167
74	Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d'Oncologie Pédiatrique. <i>Journal of Clinical Oncology</i> , 2003, 21, 1074-1081.	1.6	202
75	Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric Oncology. <i>Journal of Clinical Oncology</i> , 2001, 19, 1288-1296.	1.6	258
76	Postoperative radiotherapy in the management of adult soft tissue sarcoma of the extremities: results with two different total dose, fractionation, and overall treatment time schedules. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 879-886.	0.8	37